Skip to main content

Erythromycin Stearate

ADVERTISEMENT
Identification
Molecular formula
C37H67NO13
CAS number
643-22-1
IUPAC name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;stearic acid
State
State

At room temperature, erythromycin stearate is typically in a solid powder form.

Melting point (Celsius)
135.00
Melting point (Kelvin)
408.15
Boiling point (Celsius)
375.00
Boiling point (Kelvin)
648.15
General information
Molecular weight
733.94g/mol
Molar mass
1 062.3600g/mol
Density
1.1456g/cm3
Appearence

Erythromycin Stearate appears as a white, slightly yellowish powder. It is odorless or has a slight, characteristic odor.

Comment on solubility

Solubility of the Compound

The solubility of the compound (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; stearic acid can be quite intricate due to its complex structure and the presence of various functional groups.

Key factors influencing solubility include:

  • Polarity: The compound has both hydrophobic (e.g., long carbon chains like stearic acid) and hydrophilic (e.g., hydroxyl groups) components, suggesting that it may exhibit varying solubility in polar and nonpolar solvents.
  • Hydrogen Bonding: With multiple hydroxyl groups, this compound can engage in extensive hydrogen bonding, enhancing solubility in polar solvents like water.
  • Temperature: As with many organic compounds, increasing temperature may improve solubility, especially in solvents where thermal motion can disrupt intermolecular interactions.

Practical considerations indicate that:

  • In water: The presence of several hydroxyl groups may suggest moderate solubility.
  • In organic solvents: Increased solubility can be expected in nonpolar or less polar solvents due to hydrophobic interactions.

Overall, while it exhibits potential solubility characteristics, the exact solubility profile will ultimately depend on various factors like solvent choice, concentration, and environmental conditions. As noted, "the complexity of molecular structure often leads to unique solubility behaviors." Therefore, further empirical testing would be necessary to precisely determine its solubility in various media.

Interesting facts

Interesting Facts about (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione and Stearic Acid

This compound is a fascinating example of the complex structures found in organic chemistry. Here are some intriguing aspects to consider:

  • Stereochemistry: The compound exhibits several stereocenters, indicated by the stereochemical descriptors (R and S). This 3D arrangement can significantly influence its biological activity and interactions with other biomolecules.
  • Functional Groups: With multiple hydroxyl (-OH) groups and a dimethylamino group, this compound’s structure allows it to participate in various chemical reactions, including hydrogen bonding, which is crucial in biological systems.
  • Potential Applications: Due to its intricate structure, this compound may possess pharmaceutical properties. Compounds with similar arrangements can act as drug candidates, showcasing efficacy in targeting specific biological pathways.
  • Natural Occurrence: Many compounds resembling this structure are derived from natural products, often found in plants. This highlights the importance of biodiversity in providing potential therapeutic agents.
  • Interaction with Lipids: The presence of stearic acid, a saturated fatty acid, may suggest potential interactions with lipid membranes, affecting how the compound is absorbed and utilized in living organisms.

In summary, the study of this compound opens avenues for exploration within medicinal chemistry, offering insights into the diverse functions and applications of organic molecules in both nature and technology. The detailed stereochemical framework not only underscores molecular complexity but also invites further research into its effects and mechanisms of action in biological systems.

Synonyms
ERYTHROMYCIN STEARATE
Abboticine
Bristamycin
Gallimycin
643-22-1
Erypar
Dowmycin E
Wyamycin S
Pfizer-E
Erythrocin stearate
Qidmycin
Eratrex
Ethril
Meberyt
Erythromycin octadecanoate (salt)
Sk-erythromycin
Ethril 250
ETHRIL 500
Erythromycin stearate (salt)
Erythromycin, stearate (salt)
Erythromycin steraric acid salt
CCRIS 1504
OE 7
HSDB 4178
NCI-C55674
EINECS 211-396-1
UNII-LXW024X05M
NSC-756747
LXW024X05M
Erythromycin stearate [USP:BAN:JAN]
NSC 756747
ERYTHROMYCIN STEARATE (MART.)
ERYTHROMYCIN STEARATE [MART.]
ERYTHROMYCIN STEARATE (USP-RS)
Erythromycin stearate (USP:BAN:JAN)
ERYTHROMYCIN STEARATE [USP-RS]
DTXSID0020571
ERYTHROMYCIN STEARATE (USP IMPURITY)
ERYTHROMYCIN STEARATE [USP IMPURITY]
ERYTHROMYCIN STEARATE (USP MONOGRAPH)
ERYTHROMYCIN STEARATE [USP MONOGRAPH]
Erythromycin, octadecanoate (salt)
DTXCID20571
ERYTHROMYCIN STEARIC ACID SALT
STEARIC ACID, COMPOUND WITH ERYTHROMYCIN (1:1)
OCTADECANOIC ACID, COMPOUND WITH ERYTHROMYCIN (1:1)
(2R,3S,4S,5R,6R,8R,10R,11R,12S,13R)-5-(3,4,6-Trideoxy-3-dimethylamino-beta-D-xylo-hexopyranosyloxy)-3-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethyl-9-oxopentadecan-13-olide monostearate
211-396-1
Erythrocin
Erythromycin Stearate/Palmitate
Bristamycin (TN)
Erythromycini stearas
CHEMBL1200510
CHEBI:34742
HMS501D19
YAVZHCFFUATPRK-YZPBMOCRSA-N
ERYTHROMYCIN STEARATE [MI]
Erythromycin stearate/ >550ug/mg
HMS3264B08
Pharmakon1600-01500281
Erythromycin stearate (JP18/USP)
ERYTHROMYCIN STEARATE [JAN]
ERYTHROMYCIN STEARATE [HSDB]
CCG-39117
ERYTHROMYCIN STEARATE [VANDF]
MFCD00084690
NSC756747
ERYTHROMYCIN STEARATE [WHO-DD]
ERYTHROMYCIN STEARATE [WHO-IP]
AE22801
AT37747
NCGC00180891-01
DA-52998
ERYTHROMYCIN STEARATE [ORANGE BOOK]
SBI-0207065.P001
HY-108875
CS-0031206
ERYTHROMYCINI STEARAS [WHO-IP LATIN]
D02184
Erythromycin stearate for impurity S identification
SR-01000872741
SR-01000872741-1
Erythromycin octadecanoate salt;Abboticine;Bristamycin
Q27283244
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;octadecanoic acid